Salix Pharmaceuticals News

Catalyst trades in the biopharma sector can provide big profits if traded correctly.

Salix Pharmaceuticals, Ltd. today announced that numerous presentations and educational activities related to the investigation of several of the Company's products or relevant disease states are scheduled to take place during Digestive Disease Week DDW 2012.

's stock had its "neutral" rating reaffirmed by Zacks in a report released on Wednesday.

Salix Pharmaceuticals today had its estimates increased by Jefferies after the company beat earnings estimates.

The analysts wrote, "Salix reported a nice Q1 with in-line revenue and 11 cents EPS upside to consensus .

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

The Raleigh company had revenue of $171.1 million for the quarter, up from $105.9 percent in the first quarter of 2011.

Progenics Pharmaceuticals, Inc. announced today that it will host a conference call and webcast to discuss its financial results for the first quarter on Tuesday, May 8, 2012 at 8:30 a.m. EDT.

Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch.

Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act goal date for the Agency's Priority Review of the New Drug Application for Crofelemer 125 mg tablets for the proposed indication for the control and symptomatic relief of diarrhea in patients with human ... (more)